MAZE Maze Therapeutics, Inc.

NASDAQ
$26.05

Maze Therapeutics, Inc. (MAZE) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.79 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -5.2% since its last earnings release on August 11, 2026.

Maze Therapeutics Reported In-line with Estimates
Tuesday, August 11, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 4:00 PM ET
Earnings Whisper
-
vs ($0.79)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $26.63

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Maze Therapeutics, Inc.

Maze Therapeutics Inc. is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases. Maze Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif.

Sector

Healthcare

Industry

Biotechnology

Held By 4 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.